Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

LncRNA NORAD Promotes Spinal Cord Injury via miR-22-3p/PTEN Axis to Regulate Oxidative Stress and Inflammation in Neuronal Cells

Zhang C., Chen L., Pan Y., Yu S., Wang Q., Chen Y.

Retrospective Study on Spinal Cord Injury, Neuroinflammation, Chronic Inflammation, published in Global Spine J (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Global Spine J (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42298877
PMCID
PMC13272196
DOI
10.1177/21925682261432143

Abstract (original English)

Study DesignRetrospective Study.ObjectiveSpinal cord injury (SCI) is a severe central nervous system trauma. To explore the regulatory mechanism of long non-coding RNA (lncRNA) NORAD in SCI.MethodsEighty healthy controls and 100 SCI patients were enrolled. Meanwhile, SCI animal models and LPS-induced cell models were established. Basso-Beattie-Bresnahan (BBB) scoring was performed to monitor hind-limb motor recovery. The NORAD biological function was evaluated through RT-qPCR, CCK-8 experiments, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and the measurement of oxidative stress and metabolism-related indicators. The targeting relationships were verified through RIP experiments and dual-luciferase experiments.ResultsNORAD exhibited high expression in SCI patients and possessed good diagnostic utility for this disease. Its high expression may also be associated with the severity of injury. In SCI rats, inhibiting NORAD significantly improved the recovery of motor function and alleviated oxidative stress, cellular damage, and neuroinflammation, indicating a pro-injury role of NORAD during SCI pathogenesis. In addition, NORAD was highly expressed in the LPS-induced cell model, and promoted cellular damage, apoptosis, inflammatory responses, and oxidative stress by targeting and inhibiting miR-22-3p. While miR-22-3p directly targeted and inhibited PTEN, which was also

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research